Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to $493000.0.

  • Janux Therapeutics' Cash from Financing Activities fell 7010.31% to $493000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $388.7 million, marking a year-over-year increase of 1870.25%. This contributed to the annual value of $713.2 million for FY2024, which is 109774.8% up from last year.
  • Latest data reveals that Janux Therapeutics reported Cash from Financing Activities of $493000.0 as of Q3 2025, which was down 7010.31% from $954000.0 recorded in Q2 2025.
  • In the past 5 years, Janux Therapeutics' Cash from Financing Activities ranged from a high of $386.6 million in Q4 2024 and a low of -$843000.0 during Q3 2021
  • For the 5-year period, Janux Therapeutics' Cash from Financing Activities averaged around $64.5 million, with its median value being $892500.0 (2023).
  • In the last 5 years, Janux Therapeutics' Cash from Financing Activities crashed by 245454.55% in 2021 and then soared by 15790000.0% in 2023.
  • Over the past 5 years, Janux Therapeutics' Cash from Financing Activities (Quarter) stood at $164000.0 in 2021, then rose by 16.46% to $191000.0 in 2022, then soared by 335.08% to $831000.0 in 2023, then skyrocketed by 46428.28% to $386.6 million in 2024, then tumbled by 99.87% to $493000.0 in 2025.
  • Its Cash from Financing Activities was $493000.0 in Q3 2025, compared to $954000.0 in Q2 2025 and $554000.0 in Q1 2025.